Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era
Christopher F. Theriau, Yuchen Li, Deborah Akurang, Sara M. Moore, Rosalyn A. Juergens, Natasha B. Leighl, Paul Wheatley-Price · 2026
Read Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era by Christopher F. Theriau, Yuchen Li, Deborah Akurang, Sara M. Moore, Rosalyn A. Juergens, Natasha B. Leighl, Paul Wheatley-Price (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13206130.txt.
Description
Christopher Theriau and six colleagues audit an old chemotherapy drug's performance now that immunotherapy dominates lung cancer care, in a study published in two thousand twenty-six. Docetaxel has been a standard later-line treatment for over twenty years. Real-world results in the checkpoint inhibitor era were undocumented.
Two hundred eighty-five patients receiving docetaxel as second or later therapy across multiple centers were analyzed. Median age was sixty-two; most had good performance status and adenocarcinoma. Median exposure was only three cycles. Survival from docetaxel start was the primary endpoint, with subgroup predictors examined. Benchmarking older drugs against modern expectations tells clinicians what to honestly promise patients reaching this line of therapy.
Catalog record
| CREATOR | Christopher F. Theriau, Yuchen Li, Deborah Akurang, Sara M. Moore, Rosalyn A. Juergens, Natasha B. Leighl, Paul Wheatley-Price |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |